2026-08-04
ingest+verify — omega-3 fatty-acid evidence and oxidation-claim audit
User-requested audit of a Reddit discussion claiming that dietary omega-3 fats oxidize continuously at body temperature, that omega-3 essentiality rests only on flawed 1930s studies, that dietary omega-3/omega-6 suppresses a beneficial endogenous replacement pathway, and that oxidation explains Inuit bleeding and cardiovascular disease.
Added and independently verified omega-3-fatty-acids as a family-level compound page separating whole fish, nutritional mixed EPA+DHA, pharmacologic purified EPA, concentrated EPA+DHA, and ALA. The evidence synthesis preserves the established triglyceride, membrane/oxylipin and SPM biology while keeping hard outcomes formulation- and population-specific: VITAL/ASCEND/STRENGTH/OMEMI were neutral on their primary composites, REDUCE-IT was positive for prescription EPA in selected statin-treated high-risk adults, and PISCES was positive for mixed fish oil in maintenance hemodialysis.
The verifier added the human ALA-deficiency/repletion evidence, clarified ALA Adequate Intake versus a nonexistent omnibus omega-3 RDA, distinguished normal n-9 Mead-acid production during essential-fatty-acid deficiency from de-novo n-3/n-6 synthesis, added the peer-reviewed 2026 atrial-fibrillation dose/risk synthesis, and grounded the Inuit section in the historical ascertainment review plus the first prospective cohort. Oxidation remains a real chemical and product-quality issue, but the available short human trials do not establish weeks-long runaway in-vivo oxidation or a long-term clinical-harm threshold.
Propagated reciprocal links from dietary-fat-quality, lpl, spm-pathway, and mediterranean-diet.
update+verify — omega-3 healthspan synthesis
Re-oriented omega-3-fatty-acids from a source-thread claim audit into a durable compound-family profile. Added an exposure/outcome evidence matrix, formulation and meal-dependent pharmacokinetics, EPA+DHA dose accounting, erythrocyte exposure-biomarker interpretation, structured atrial-fibrillation/bleeding/lipoprotein monitoring, operational product-identity and oxidation criteria, and an explicit distinction between food-pattern evidence, ordinary supplementation, and prescription formulations.
Added bischoff-ferrari-2025-do-health-biological-aging as the atomic source for the DO-HEALTH Bio-Age result. The healthspan framing now recognizes small randomized changes in PC-PhenoAge, GrimAge2, and DunedinPACE while preserving the central boundary: the post-hoc Swiss-subset methylation findings are surrogate responsiveness, not evidence of longer lifespan or disability-free survival. The compound page’s aging translation gap was changed to biomarker-only, and its next experiment now requires simultaneous molecular-aging, frailty, cardiovascular-safety, disability-free-survival, and mortality endpoints.
The independent full-text verifier separated factorial marginal omega-3 effects from the literal omega-3-only GrimAge2 arm and found that the paper’s 2.9–3.8-month headline is a descriptive conversion, not a direct randomized-effect magnitude. Propagated those corrections to phenoage-2018, grimage-2019, dunedinpace-2022, and biological-age-measurement. The family page now uses clinical-stage: supplement; FDA approval remains attributable only to specific prescription esters.